Details of the Drug Reposition

General Information of This Drug (ID: DMAHJEF)

Drug Name
Betamethasone   DMAHJEF
Synonyms
betamethasone; 378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Beta-Methasone; Beta-Methasone alcohol; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
33 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Serum sickness DIS0MRKJ N.A. Approved [1]
Scalp dermatosis DISN50RG N.A. Approved [1]
Rheumatic heart disease DISCI8JQ N.A. Approved [1]
Primary cutaneous T-cell lymphoma DIS35WVW N.A. Approved [1]
Miliary tuberculosis DIS4AT5W N.A. Approved [1]
Granuloma annulare DISMOUMI N.A. Approved [1]
Exanthem DISAFOQN N.A. Approved [1]
Erythema multiforme DISKCLM1 N.A. Approved [1]
Epicondylitis DIS0R2VM N.A. Approved [1]
Disorder of orbital region DISH0ECJ N.A. Approved [1]
Diamond-Blackfan anemia DISI2SNW N.A. Approved [1]
Bursitis DISCF7Y9 N.A. Approved [1]
Aspiration pneumonitis DIS5S4DE N.A. Approved [1]
Acute adrenal insufficiency DIS66YLV N.A. Approved [1]
Inflammation DISJUQ5T 1A00-CA43.1 Approved [2]
Tinea cruris DIS5JC14 1F28.3 Approved [1]
Mycosis fungoides DIS62RB8 2B01 Approved [1]
Autoimmune haemolytic anaemia DIS7MS3M 3A20 Approved [1]
Angioedema DIS90QDN 4A00.15 Approved [1]
Systemic lupus erythematosus DISI1SZ7 4A40.0 Approved [1]
Sarcoidosis DISE5B8Z 4B20.5 Approved [1]
Congenital adrenal hyperplasia DISG873W 5A71.01 Approved [1]
Addison disease DIS7HNOH 5A74.0 Approved [1]
Multiple sclerosis DISB2WZI 8A40 Approved [1]
Cerebral edema DIS4GHSB 8D60.1 Approved [1]
Allergic rhinitis DIS3U9HN CA08.0 Approved [1]
Severe asthma DISAVQI3 CA23 Approved [1]
Crohn disease DIS2C5Q8 DD70 Approved [1]
Inflammatory bowel disease DISGN23E DD72 Approved [1]
Skin disease DISDW8R6 EA00-EM0Z Approved [1]
Psoriasis DIS59VMN EA90 Approved [1]
Dermatitis herpetiformis DIS0TC0G EB44 Approved [1]
Psoriatic arthritis DISLWTG2 FA21 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 33 Indications(s)
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pemphigus DISZAZ6M N.A. Withdrawn [3]
------------------------------------------------------------------------------------
4 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Thyroiditis DISTCV24 N.A. Discontinued in Phase 3 [4]
Tendinitis DISS7ANY N.A. Discontinued in Phase 3 [5]
Acute lymphocytic leukaemia DISPX75S 2B33.3 Discontinued in Phase 3 [6]
Ankylosing spondylitis DISRC6IR FA92.0 Discontinued in Phase 3 [7]
------------------------------------------------------------------------------------
8 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Exfoliative dermatitis DISQEWIW N.A. Discontinued in Phase 2 [8]
Tenosynovitis DISR5H9R N.A. Discontinued in Phase 2 [9]
Humoral hypercalcemia of malignancy DISQQ62D N.A. Discontinued in Phase 2 [10]
Nephrotic syndrome DISSPSC2 N.A. Discontinued in Phase 2 [11]
Autoimmune disease DISORMTM 4A40-4A45 Discontinued in Phase 2 [12]
Seborrhoeic dermatitis DISNWVJU EA81 Discontinued in Phase 2 [13]
Contact dermatitis DISQ3AU0 EK0Z Discontinued in Phase 2 [14]
Musculoskeletal disorder DISPPN0O FA00-FC0Z Discontinued in Phase 2 [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Indications(s)
2 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Atopic dermatitis DISTCP41 EA80 Discontinued in Phase 1 [16]
Arthritis DIST1YEL FA20 Discontinued in Phase 1 [17]
------------------------------------------------------------------------------------
6 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Trichinellosis DISUR2ZW N.A. Investigative [1]
Synovitis DISW2GPY N.A. Investigative [1]
Classic Hodgkin lymphoma DISV1LU6 N.A. Investigative [1]
Beta-thalassemia major DISW06BV N.A. Investigative [1]
Acquired thrombocytopenia DISXH01C N.A. Investigative [1]
Follicular lymphoma DISVEUR6 2A80 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Indications(s)

References

1 Betamethasone FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7061).
3 Pharmacology of Exenatide in Pediatric Sepsis
4 Everolimus on CKD Progression in ADPKD Patients
5 Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy
6 Zoledronic Acid in MS-patients With Osteoporosis
7 An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
8 Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer
9 Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma
10 Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis
11 WR 279,396 Open Label Treatment Protocol in Tunisia
12 Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery
13 ClinicalTrials.gov (NCT00993421) A Weight Loss Study in Overweight Men and Women. U.S. National Institutes of Health.
14 Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
15 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
16 A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
17 Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer